XNAS · BBOT
-0.58% · -$0.0200 · Vol 566.2K
Market closed · last close 4:00 PM ET · price as of 16:00:26 ET
BridgeBio Oncology Therapeutics, Inc. Common Stock

BridgeBio Oncology Therapeutics, Inc. Common Stock

PHARMACEUTICAL PREPARATIONS
$3.42
Card
Relationship Map

Follow $BBOT

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $BBOT by email

Veridion Score

BETALOW CONF · 5 of 6 factors measuredMethodology
Sentiment absence reason unknown
BBOT
BridgeBio Oncology Therapeutics, Inc. Common Stock
Thu Oct 8 · market closed · Markets closed · resumes Fri 9:30 ET
Lower range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

38/ 100
Veridion Score
Lower range · LOW confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 5 of 6 factors measured · Thu Oct 8 · market closed · Markets closed · resumes Fri 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is BBOT moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading BBOT catalysts
About BridgeBio Oncology Therapeutics, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Listed since
2025
Employees
88
Country
US

BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$3.43
Day high
$3.43
Day low
$3.27
Previous close
$3.44
52W high
$13.73
-75.09% from high
52W low
$3.27
1% of range
Market cap
$275.8M
Beta
1.76
Shares out
80.2M
Volume
566.2K
0.84× rel vol
Avg volume
673K
VWAP
$3.39
Price history computed in-house
1W
-12.08%
1M
-49.37%
3M
-58.89%
1Y
-72.35%
YTD
-72.68%
SMA 50 $6.97 · below
SMA 200 $8.89 · below
52W position 1%

BBOT overview

Veridion Score
38
Registered · 2026-10-08
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around BBOT.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading BBOT Form 4 filings
Public disclosures

Congress activity in BBOT

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

BBOT contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for BBOT in this window.
Lobbying spend

BBOT lobbying filings, year to date.

Registered lobbying filings matched to BridgeBio Oncology Therapeutics, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for BBOT in this window.
Loading news for BBOT
Analyst ratings
Sovereign unlock shows live analyst consensus for BBOT.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.